Analysts Set $16.75 Target Price for Trevi Therapeutics Inc (NASDAQ:TRVI)

Trevi Therapeutics Inc (NASDAQ:TRVI) has been assigned an average broker rating score of 1.25 (Strong Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy rating and three have issued a strong buy rating on the company.

Analysts have set a 1 year consensus price target of $16.75 for the company and are anticipating that the company will post ($0.63) EPS for the current quarter, according to Zacks. Zacks has also assigned Trevi Therapeutics an industry rank of 72 out of 256 based on the ratings given to its competitors.

TRVI has been the topic of a number of recent research reports. Needham & Company LLC initiated coverage on shares of Trevi Therapeutics in a report on Monday, June 3rd. They issued a “buy” rating and a $18.00 target price on the stock. Stifel Nicolaus initiated coverage on shares of Trevi Therapeutics in a report on Monday, June 3rd. They issued a “buy” rating and a $20.00 target price on the stock. Svb Leerink initiated coverage on shares of Trevi Therapeutics in a report on Monday, June 3rd. They issued an “outperform” rating and a $14.00 target price on the stock. BMO Capital Markets initiated coverage on shares of Trevi Therapeutics in a report on Monday, June 3rd. They issued an “outperform” rating and a $15.00 target price on the stock. Finally, Leerink Swann initiated coverage on shares of Trevi Therapeutics in a report on Monday, June 3rd. They issued an “outperform” rating on the stock.

Shares of Trevi Therapeutics stock opened at $7.55 on Monday. Trevi Therapeutics has a 12 month low of $7.18 and a 12 month high of $10.62.

In other news, Director Anne Vanlent acquired 5,000 shares of the company’s stock in a transaction on Thursday, May 9th. The shares were bought at an average cost of $10.00 per share, with a total value of $50,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Jennifer L. Good acquired 11,250 shares of the company’s stock in a transaction on Thursday, May 9th. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $112,500.00. The disclosure for this purchase can be found here. Insiders acquired a total of 391,250 shares of company stock worth $3,912,500 over the last three months.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease.

Read More: What is the Ex-Dividend Date in Investing?

Get a free copy of the Zacks research report on Trevi Therapeutics (TRVI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Trevi Therapeutics (NASDAQ:TRVI)

Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.